Dexamethasone treatment modifies <i>PTGDR</i> expression levels. by Elena Marcos-Vadillo (4557103)

Dexamethasone treatment modifies <i>PTGDR</i> promoter activity. by Elena Marcos-Vadillo (4557103)

Set1 complex Set1 and Swd1 subunits associate in meiosis with highly transcribed genes, but not with chromosome axis sites. by Céline Adam (320770)

OPTN degrades GSK3β via activating LC3-mediated autophagy. by Xiao Chen Shi (8611887)

Nonequilibrium Arrhythmic States and Transitions in a Mathematical Model for Diffuse Fibrosis in Human Cardiac Tissue by Rupamanjari Majumder (128411)

“…Our study of a single myocyte-fibroblast (MF) composite, with a single myocyte coupled to fibroblasts via a gap-junctional conductance , reveals five qualitatively different responses for this composite. …”

Artificial data: influence of the nature and amount of inter-subject variability on the mean accuracy (± standard error). by Sylvain Takerkart (5659873)

Presentation_1_The subdued post-boost spike-directed secondary IgG antibody response in Ugandan recipients of the Pfizer-BioNTech BNT162b2 vaccine has implications for local vaccin... by Violet Ankunda (14799277)

“…A validated enzyme-linked immunosorbent assay (ELISA) was used to quantify SARS-CoV-2-specific IgG, IgM, and IgA antibody concentrations (ng/ml) and optical densities (ODs). …”

Relationships between each parameter relative change and stent wire mesh density. by Shunsuke Masuda (12859231)

Assessment of the membrane NMDA and AMPA receptor expression after optogenetic stimulation of hippocampal CA1 astrocytes. by Jae-Hong Kim (124622)

Table_1_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”

Table_2_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”

Table_2_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”

Table_1_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”

Platelets were inhibited by PFC administration and activated in response to LPS. by Heather F. Pidcoke (9023789)

Fig 2 - by Karolina Pawlak (13813008)

Loss of layer V pyramidal neurons of motor cortex. by Paolo d’Errico (494029)

“…Values are expressed as mean ± SEM. Scale bars: 5 mm in A; 50 µm in C.</p>…”

Sequence alignments of HBV from high-throughput bisulfite sequencing or different HBV genotypes. by Jiangpeng Feng (9287738)

OPTN does not affect cell proliferation. by Xiao Chen Shi (8611887)

Extracellular α toxin is decreased in a Δ<i>stp1</i> mutant and increased in a Δ<i>stk1</i> mutant compared to WT Newman. by Kellie Burnside (247478)

Table 1_Multi-omics-based phenotyping of AFG3L2-mutant lymphoblasts determines key factors of a pathophysiological interplay between mitochondrial vulnerability and neurodegenerati... by Menekse Oeztuerk (20756606)

“…Mutations in AFG3L2 are implicated in a spectrum of diseases, including spinocerebellar ataxia type 28 (SCA28) and spastic ataxia 5 (SPAX5), as well as other systemic conditions. …”